Budd-Chiari syndrome after BNT162b2 mRNA vaccination: two case reports.

Autor:	Lipszyc L; Department of Pharmacovigilance, Assistance Publique-Hôpitaux de Paris (AP-HP), CHU Henri Mondor, Creteil, France lorene.lipszyc@aphp.fr., Triquet L; Regional Pharmacovigilance Center, CHU de Rennes, Rennes, Bretagne, France., Giguet B; Liver disease department, CHU de Rennes, Rennes, Bretagne, France., Lambotte O; Department of Internal Medicine, Assistance Publique-Hôpitaux de Paris (AP-HP), CHU Bicetre, Le Kremlin-Bicetre, Ile-de-France, France., Babai S; Department of Pharmacovigilance, Assistance Publique-Hôpitaux de Paris (AP-HP), CHU Henri Mondor, Creteil, France.
Jazyk:	angličtina
Zdroj:	European journal of hospital pharmacy : science and practice [Eur J Hosp Pharm] 2024 Jul 22. Date of Electronic Publication: 2024 Jul 22.
DOI:	10.1136/ejhpharm-2023-003997
Abstrakt:	Budd-Chiari syndrome (BCS) is a rare disease characterised by an obstruction in the hepatic venous outflow. We describe two cases of patients hospitalised a few days after tozinameran vaccination. Liver tests and medical imaging were carried out, and BCS was diagnosed. After treatment including anticoagulant therapy, the first patient improved clinically, unlike the second patient with persistent hepatic thrombosis. According to the WHO-UMC causality assessment system, the vaccine's share was assessed as 'probable' for the first patient as BCS occurred during anticoagulant therapy, and 'possible' for the second patient as no other aetiology was found. Further epidemiological studies are needed to confirm or refute the causal relationship between BCS and tozinameran vaccination. Competing Interests: Competing interests: None declared. (© European Association of Hospital Pharmacists 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu